Article
Immunology
Haoyu Wang, Ruiyuan Yang, Ke Zhou, Suyan Wang, Cheng Cheng, Dan Liu, Weimin Li
Summary: This study conducted a meta-analysis to explore the prognostic value of pretreatment CRP level in NSCLC patients treated with immune checkpoint inhibitors. The results showed that higher CRP levels were associated with worse overall survival and progression-free survival.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Immunology
Xiao-Juan Chen, Ai-Qun Ren, Liang Zheng, En-Dian Zheng
Summary: KDM5C alterations are associated with predictive value for cancer patients receiving ICIs, with patients having KDM5C alterations showing better survival rates. KDM5C alterations also correlate with increased tumor immunogenicity and anti-tumor immunity.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Chengming Liu, Sihui Wang, Sufei Zheng, Fei Xu, Zheng Cao, Xiaoli Feng, Yan Wang, Qi Xue, Nan Sun, Jie He
Summary: Immunotherapy has drawn significant attention in oncology, but traditional biomarkers for anti-PD-1 therapy may not be suitable for NSCLC clinical practice due to technical biases. The novel BRGPI, a gene expression-based index, showed strong potential as a predictive tool for identifying NSCLC patients who may benefit from anti-PD-1 immunotherapy, outperforming PD-L1 as a prognostic factor. Patients with low BRGPI and high PD-L1 levels were found to derive more clinical benefits from anti-PD-1 therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Genhao Zhang, Xianping Lv, Qiankun Yang, Hongchun Liu
Summary: This study found that upregulated HM13 in HCC is associated with poor prognosis, enhanced proliferation and migration potential of HCC cells. Additionally, patients with high HM13 expression might be more sensitive to immunotherapy.
Article
Immunology
Lin Chen, Qiaodan Zhou, Junjie Liu, Wei Zhang
Summary: In this study, we identified CTNNB1-MUT as a potential biomarker for HCC immunotherapy patients, as it can identify those who are less likely to benefit from ICIs.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Liu Li, Kuang Tianrui, Li Chunlei, Qiu Zhendong, Chen Xiaoyan, Deng Wenhong
Summary: The presence of HYDIN mutations in melanoma patients may serve as a potential predictive biomarker for the efficacy of immune checkpoint inhibitors (ICIs) treatment.
Review
Oncology
Ruixia Song, Fengsen Liu, Yu Ping, Yi Zhang, Liping Wang
Summary: Immune checkpoint inhibitors (ICIs) have greatly improved the treatment outcomes for various malignancies, but only a small percentage of patients respond significantly. Accurate identification of responders and timely administration of ICIs are critical issues. Recent advancements at the intersection of oncology, immunology, biology, and computer science have provided predictive biomarkers for ICI efficacy. Non-invasive markers have been shown to have better availability and accuracy in predicting ICI efficacy compared to invasive markers.
BIOMARKER RESEARCH
(2023)
Review
Oncology
Kui Zang, Liangliang Hui, Min Wang, Ying Huang, Xingxing Zhu, Bin Yao
Summary: TIM-3 was identified as an independent adverse prognostic indicator for overall survival in various types of cancer. It plays a crucial role in tumor immune responses, supporting its potential as a promising target for cancer immunotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Xinlong Zheng, Longfeng Zhang, Lin Wu, Jun Zhao, Jianguo Sun, Yong Fang, Jin Zhou, Qian Chu, Yihong Shen, Zhenzhou Yang, Lijin Chen, Meijuan Huang, Xiaoyan Lin, Zhenhua Liu, Peng Shen, Zhijie Wang, Xin Wang, Huijuan Wang, Zhengbo Han, Anwen Liu, Hongmei Zhang, Feng Ye, Wen Gao, Fang Wu, Zhengbo Song, Shengchi Chen, Chenzhi Zhou, Qian Wang, Chunwei Xu, Dingzhi Huang, Xiaobin Zheng, Qian Miao, Kan Jiang, Yiquan Xu, Shiwen Wu, Haibo Wang, Qiuyu Zhang, Shanshan Yang, Yujing Li, Sihui Chen, Gen Lin
Summary: This study investigated the predictive value of baseline CRP levels on the efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced LSCC. The results showed that elevated CRP levels were associated with a reduction in treatment efficacy in the combination therapy group.
Article
Cell Biology
Xinwen Wang, Liangming Wang, Weifeng Xu, Xinwu Wang, Dianshan Ke, Jinluan Lin, Wanzun Lin, Xiaochun Bai
Summary: Osteosarcoma has been classified into two clusters based on immune signatures: immunity high and immunity low. The immunity high subtype is associated with favorable prognosis, high immune cells infiltration, and benefit to immunotherapy; while the immunity low subtype has poor prognosis, low immune cell infiltration, and cancer-related pathways. The study identified TYROBP as a key immunoregulatory gene associated with CD8(+) T cell infiltration and established an immune-related prognostic model for predicting the survival time of osteosarcoma patients.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Oncology
Menglu Dai, Wei Wu
Summary: This meta-analysis investigated the association between C-reactive protein to albumin ratio (CAR) and the prognosis of cancer patients receiving immune checkpoint inhibitors (ICIs). The results indicated that high CAR expression was associated with worse survival outcomes. CAR is a potential biomarker for selecting cancer patients who would benefit from ICIs, as it is easily accessible and cost-effective.
FRONTIERS IN ONCOLOGY
(2023)
Review
Immunology
Ziyang Mao, Xiaohui Jia, Panpan Jiang, Qinyang Wang, Yajuan Zhang, Yanlin Li, Xiaolan Fu, Min Jiao, Lili Jiang, Zhiyan Liu, Hui Guo
Summary: This study found that concomitant use of opioids during ICI treatment has an adverse effect on patient prognosis, while the use of non-steroidal anti-inflammatory drugs (NSAIDs) does not significantly affect the prognosis in patients treated with ICIs.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Xin-Cheng Mao, Chun-Cheng Yang, Ya-Fei Yang, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Yu-Chuan Yan, Zhao-Ru Dong, Dong-Xu Wang, Tao Li
Summary: This study reviewed the association between peripheral cytokines and cancer immunotherapy, and found that IL-6 and IL-8 were negatively associated with overall survival of cancer patients receiving immune checkpoint inhibitors. However, high heterogeneity was observed for IL-6.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Almog Shalit, Panagiotis Sarantis, Evangelos Koustas, Eleni-Myrto Trifylli, Dimitris Matthaios, Michalis V. Karamouzis
Summary: Immune checkpoint inhibitors have improved the prognosis of many cancers but also lead to a new category of adverse effects called immune-related adverse effects. Endocrine dysfunctions are commonly observed immune-related adverse effects that can be successfully treated if discovered early but have the potential for life-threatening consequences if left undiagnosed. Thus, it is imperative to establish predictive biomarkers that indicate the risk of endocrinopathy occurrence and can guide clinical decisions.
Review
Medicine, General & Internal
Inbar Nardi Agmon, Osnat Itzhaki Ben Zadok, Ran Kornowski
Summary: Immune checkpoint inhibitors (ICIs) are an effective treatment for various cancers, but they also carry the risk of immune-related adverse events (irAEs), including cardiac toxicity. Evidence suggests an increased risk of cardiovascular events and accelerated atherosclerosis with ICIs treatment, as well as other cardiovascular adverse events. However, there are currently no identified risk factors, monitoring strategies, or diagnostic tests for cardiac complications, which poses challenges in timely recognition and optimal management.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Immunology
Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Cheng-Long Han, Guang-Xiao Meng, Jun-Shuai Xue, Zhao-Ru Dong, Yu-Chuan Yan, Jian-Guo Hong, Zhi-Qiang Chen, Dong-Xu Wang, Tao Li
Summary: Poor liver function is associated with a poor prognosis in HCC patients receiving ICIs. The ALBI score is a simpler and reliable method for evaluating liver function and determining treatment options. Despite the relatively short survival time of patients with impaired liver function, ICIs still show great potential for therapeutic applications.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Oncology
Long-Shan Yang, Lun-Jie Yan, Guang-Xiao Meng, Zi-Niu Ding, Sheng-Yu Yao, Hai-Chao Li, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li
Summary: Glycemic index (GI), glycemic load (GL), and daily carbohydrates intake are associated with the risk of hepatocellular carcinoma (HCC). A high glycemic load diet is linked to an increased risk of HCC in individuals with viral hepatitis, while no significant association is found in those without viral hepatitis. Therefore, a low glycemic load diet is recommended to reduce the risk of HCC in individuals with viral hepatitis.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
(2023)
Review
Gastroenterology & Hepatology
Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Guang-Xiao Meng, Jun-Shuai Xue, Cheng-Long Han, Zhao-Ru Dong, Jian-Guo Hong, Zhi-Qiang Chen, Dong-Xu Wang, Tao Li
Summary: This meta-analysis examined the relationship between alpha-fetoprotein (AFP) response and survival outcomes in hepatocellular carcinoma (HCC) patients treated with targeted therapy or immune checkpoint inhibitors (ICIs). The results showed that AFP decrease was associated with better prognosis, while AFP increase was associated with worse prognosis. Furthermore, a decrease in AFP greater than 20% within 8 weeks may be the appropriate definition for early AFP response in predicting therapy efficacy.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Cheng-Long Han, Bao-Wen Tian, Chun-Cheng Yang, Ya-Fei Yang, Yun-Long Ma, Zi-Niu Ding, Lun-Jie Yan, Hui Liu, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Dong-Xu Wang, Tao Li
Summary: Fatty liver is a risk factor for hepatocellular carcinoma in patients with Hepatitis B or C virus, although the results are contradictory. Biopsy-proven fatty liver is a significant risk factor for hepatocellular carcinoma in these patients. Suitable interventions should be given to prevent or attenuate the risk of hepatocellular carcinoma in these individuals.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Oncology
Cheng-Long Han, Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Xin-Cheng Mao, Jin-Cheng Tian, Jun-Shuai Xue, Si-Yu Tan, Zhao-Ru Dong, Yu-Chuan Yan, Jian-Guo Hong, Zhi-Qiang Chen, Dong-Xu Wang, Tao Li
Summary: This study aimed to evaluate the impact of macrovascular invasion (MVI) or extrahepatic spread (EHS) on the efficacy and safety of immune checkpoint inhibitors (ICIs) among hepatocellular carcinoma (HCC) patients. The findings indicated that MVI has a significant impact on efficacy, while the impact of EHS is not significant.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Oncology
Bao-Wen Tian, Cheng-Long Han, Han-Chao Wang, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Xin-Cheng Mao, Jin-Cheng Tian, Jun-Shuai Xue, Long-Shan Yang, Si-Yu Tan, Zhao-Ru Dong, Yu-Chuan Yan, Dong-Xu Wang, Tao Li
Summary: The purpose of this study is to explore the relationship between liver metastasis and survival outcomes of patients receiving ICIs treatment. The results showed that patients with liver metastasis receiving ICIs treatment had worse overall survival and progression-free survival. The prognostic effect of liver metastasis differed among different cancer types and metastatic sites.
CLINICAL & EXPERIMENTAL METASTASIS
(2023)
Review
Oncology
Zi-Niu Ding, Guang-Xiao Meng, Jun-Shuai Xue, Hui Liu, Long-Shan Yang, Rui-Zhe Li, Xin-Cheng Mao, Yu-Chuan Yan, Dong-Xu Wang, Zhao-Ru Dong, Tao Li
Summary: We aimed to determine the optimal treatment option for advanced hepatocellular carcinoma (HCC), considering systemic therapy with or without locoregional therapy. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), grade 3-4 treatment-related adverse events (TRAEs), and incidence of treatment discontinuation due to adverse events were the outcomes of interest. The surface under the cumulative ranking curve (SUCRA) probability values were used to rank the interventions. In total, 23 randomized-controlled trials with 14,303 patients were included. Lenvatinib plus transcatheter arterial chemoembolization (TACE) ranked best in terms of OS benefit (SUCRA: 0.99). Immuno-oncology (IO)-multikinase inhibitor (MKI)/vascular endothelial growth factor (VEGF) inhibitor combinations had a higher probability of providing better OS compared to IOIO combinations. IO monotherapies demonstrated superior safety profile while combination therapies caused more toxicity in general. We conclude that combination therapies achieve remarkable efficacy in patients with advanced HCC and clinical decision making requires a careful balance of efficacy versus risk.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Review
Oncology
Lun-Jie Yan, Long-Shan Yang, Yu-Chuan Yan, Si-Yu Tan, Zi-Niu Ding, Hui Liu, Dong-Xu Wang, Zhao-Ru Dong, Tao Li
Summary: This study investigated the association between different anthropometric indicators and the risk of primary liver cancer. Adiposity was found to be strongly associated with an increased risk of liver cancer, with waist-to-hip ratio and waist-to-height ratio showing the strongest association.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Nutrition & Dietetics
Long-Shan Yang, Lun-Jie Yan, Yu-Chuan Yan, Zi-Niu Ding, Hui Liu, Si-Yu Tan, Zhao-Ru Dong, Dong-Xu Wang, Tao Li
Summary: This meta-analysis study reveals a significant association between obesity and mortality in primary liver cancer patients, with regional and gender differences. Men with excess body mass index (BMI) have a higher risk of liver cancer-related mortality compared to women. However, there is no significant association between obesity and all-cause mortality or recurrence risk in primary liver cancer.
Article
Pharmacology & Pharmacy
Yun-Long Ma, Ya-Fei Yang, Han-Chao Wang, Chun-Cheng Yang, Lun-Jie Yan, Zi-Niu Ding, Bao-Wen Tian, Hui Liu, Jun-Shuai Xue, Cheng-Long Han, Si-Yu Tan, Jian-Guo Hong, Yu-Chuan Yan, Xin-Cheng Mao, Dong-Xu Wang, Tao Li
Summary: This study combines copper homeostasis and cuproptosis for the first time to demonstrate the overall potential risk of copper-related biological processes in hepatocellular carcinoma (HCC). A prognostic scoring system was constructed to forecast tumor microenvironment changes and assist in choosing therapy strategies for HCC patients.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Nutrition & Dietetics
Long-Shan Yang, Ze-Yi Zhang, Lun-Jie Yan, Yu-Chuan Yan, Si-Yu Tan, Dong-Xu Wang, Zhao-Ru Dong, Tao Li
Summary: Depression is common among cancer patients, and there may be a potential link between caffeine intake and depression. However, the relationship between caffeine and depression in cancer patients is still uncertain.
NUTRITION RESEARCH
(2023)
Article
Cell Biology
Yu-Chuan Yan, Guang-Xiao Meng, Chun-Cheng Yang, Ya-Fei Yang, Si-Yu Tan, Lun-Jie Yan, Zi-Niu Ding, Yun-Long Ma, Zhao-Ru Dong, Tao Li
Summary: In this study, the DAGLA/2-AG axis is found to promote HCC progression by regulating cell proliferation, invasion, and metastasis. Furthermore, DAGLA induces resistance to lenvatinib therapy during HCC treatment. Therefore, inhibiting the DAGLA/2-AG axis could be a novel therapeutic strategy to inhibit HCC progression and enhance the therapeutic effects of TKIs.
CELL DEATH & DISEASE
(2023)